James Madison Institute lauds ‘Right to Try’ legislation
The Trump administration drew support this week from a free-market think tank nestled in the capital for signing legislation making experimental medicines and treatment options available to terminally ill patients.
“On this historic occasion, we would like to thank President Donald Trump, the leadership in Congress, and the thousands of stakeholders who have labored for years to make ‘Right to Try’ a reality,” James Madison Institute (JMI) CEO and President Bob McClure said in a statement.
Donald Trump receives kudos for signing the Right to Try Act.
According to the White House, the bill specifically “amends Federal law to allow certain unapproved, experimental drugs to be administered to terminally ill patients who have exhausted all approved treatment options and are unable to participate in clinical drug trials.”
McClure said JMI worked diligently with those involved in the process to get the bill to the president’s desk.
“As a result of this groundbreaking legislation, Americans will now have the opportunity and freedom to choose medical options that they otherwise would not have,” McClure continued. “It is a testament to the commitment of the president and the Congress that we can count this as a win for free-market health care.”